Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822168 | 0.81 | MAPT (0.43) | SMN1; SMN2MAPTKDM4ETDP1KMT2A | |
| SCHEMBL14073800 | 0.80 | MAPT (0.49) | SMN1; SMN2MAPTKDM4ETDP1MEN1 | |
| SCHEMBL17192803 | 0.76 | KMT2A (0.38) | SMN1; SMN2MAPTKDM4ETDP1MEN1 | |
| SCHEMBL264821 | 0.76 | ATM (0.71) | SMN1; SMN2MAPTKDM4EMEN1KMT2A | |
| SCHEMBL2776027 | 0.76 | ATM (0.71) | SMN1; SMN2MAPTKDM4EMEN1KMT2A | |
| SCHEMBL10041972 | 0.76 | ATM (0.71) | SMN1; SMN2MAPTKDM4EMEN1KMT2A | |
| SCHEMBL9542830 | 0.75 | ATM (0.40) | SMN1; SMN2MAPTKDM4ETDP1MEN1 | |
| SCHEMBL17134258 | 0.75 | NPSR1 (0.49) | MEN1KMT2APOLBHTTALDH1A1 | |
| SCHEMBL17134257 | 0.75 | NPSR1 (0.49) | MEN1KMT2APOLBHTTALDH1A1 | |
| SCHEMBL18785495 | 0.74 | DRD4 (0.45) | SMN1; SMN2MAPTKDM4ETDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104382924-B | N6 substituted adenosines derivative and N6 substituted adenines derivatives and application thereof | 中国医学科学院药物研究所 | 2017-12-22 | — | — | CN | disclosed |
| CN-102812033-B | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-104382924-A | N6-substituted adenosine derivative and N6-substituted adenine derivative and application thereof | INST MATERIA MEDICA CAMS | 2015-03-04 | — | — | CN | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-7205330-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-5608069-A | TREATMENT OF NERVOUS SYSTEM DISORDERS WITH GAMMA-AMINOBUTYRIC ACID | NOVO NORDISK A/S (DK) | 1997-03-04 | — | — | US | disclosed |
| CN-1128990-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK AS (DK) | 1996-08-14 | — | — | CN | disclosed |
| EP-0705246-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000483-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | SMN1; SMN2 3962/4885MAPT 4108/4885KDM4E 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.